Participation in randomised, open-label, phase 3 trial of the combination for treatment of multiple myeloma

Pirogov Medical University has took a part in the international randomised, open-label, phase 3 trial of the combination of pomalidomide, bortezomib, and dexamethasone for treatment of multiple myeloma.

This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled.

It has been demonstrated that patients with relapsed or refractory multiple myeloma who previously received lenalidomide had significantly improved progression-free survival when treated with pomalidomide, bortezomib, and dexamethasone compared with bortezomib and dexamethasone. This study supports use of pomalidomide, bortezomib, and dexamethasone as a treatment option in patients with relapsed or refractory multiple myeloma who previously received lenalidomide.

Read more in

Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019. 20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4.

Back